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Background/Aims: The aim of this study was to compare the clinical features 
and outcomes of ulcerative colitis (UC) according to the age of onset in Korea. 
Methods: A total of 1,141 patients who were diagnosed with UC between July 1987 
and November 2013 at 11 tertiary hospitals were enrolled. The baseline disease 
characteristic and disease state at onset, treatment during the disease course 
were retrospectively reviewed among patients with young-onset (YO, < 20 years) 
and adult-onset (AO, ≥ 20 years). Severe outcome was defined as use of intrave-
nous (IV) steroids, infliximab, immunosuppressant, or UC-related operation. 
Results: There were 55 YO patients (mean age, 17.8 ± 2.4) and 1,086 AO patients 
(mean age, 43.0 ± 13.6). High Mayo scores (7.7 ± 3.0 vs. 5.6 ± 2.7, p = 0.000), exten-
sive UC (52.7% vs. 25.8%, p = 0.000) and IV steroid (41.8% vs. 18.0%, p = 0.000), 
immunosuppressant (47.3% vs. 26.9%, p = 0.002), and infliximab (20.0% vs. 7.2%, 
p = 0.001) use were more frequent in the YO than in the AO group. According to 
multivariate analysis, severe outcomes were related to YO disease (hazard ratio 
[HR], 2.18; 95% confidence interval [CI], 1.27 to 3.71), body mass index < 23 kg/m2 
(HR, 1.46; 95% CI, 1.07 to 2.00), severe (HR, 2.29; 95% CI, 1.36 to 3.38), and moder-
ate (HR, 2.48; 95% CI, 1.67 to 3.67) disease, extensive UC (HR, 2.90; 95% CI, 1.79 to 
4.69), UC-related admission (HR, 63.89; 95% CI, 20.41 to 200.02), and oral steroid 
use (HR, 0.51; 95% CI, 0.39 to 0.67). 
Conclusions: UC with YO presented with more advanced clinical features at 
onset and more severe outcomes than the AO. YO cases require careful manage-
ment and intense treatment strategies.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic and relapsing inflam-
matory disease of the colon and rectum that affects con-
tinuously. Although its exact etiology remains unknown, 
UC is thought to arise from an interaction between genet-
ic and environmental factors. Given its chronic and re-
lapsing nature, UC can seriously impact quality of life [1].
The worldwide incidence of UC varies greatly accord-
ing to geographic location. The prevalence ranges be-
tween 0.5 and 24.5 per 100,000 persons [2]. The annual 
incidence of UC in Asia is lower than that in Western 
regions [3,4]. However, the incidence of UC has in-
creased in Asian countries secondary to the westerniza-
tion of lifestyle and diagnostic modalities [5,6], especially 
among the younger age patients [7]. Due to these chang-
es, UC is expected to become an increasing a clinical 
burden in Asia.
UC has bimodal peaks for incidence. There is a small 
peak in incidence around the age of 20 years and a sec-
ond larger peak around the age of 60 years [8]. Recently, 
it was recognized that clinical characteristics and dis-
ease outcomes differ according to the age of diagnosis. 
However, these studies have shown conflicting results. 
Some studies have found that early-onset UC produce a 
more severe phenotype [9] and requires more frequent 
operation than does late-onset UC [10]. Additionally, a 
larger proportion of patients with pediatric-onset UC 
require immunosuppressive and biologic agents com-
pared to those with adult-onset (AO) disease [11]. In con-
trast, late-onset UC is related to refractoriness to thera-
py [12] and aggressive development of colorectal cancer 
[13]. Another study reported that age at diagnosis had no 
effect on prognosis [14]. 
In Korea, the clinical differences and effects related 
to age of onset in patients with UC have not been well 
established. A previous study reported that certain clin-
ical features and disease extent more severe when UC 
is diagnosed at a younger age, as compared to when it 
is diagnosed later in life. However, the disease course 
and prognosis may not differ from those of their older 
counterparts [15]. Given this background, the aim of the 
present study was to compare the clinical features and 
disease outcomes of UC according to the age of onset 
in Korea.
METHODS
Study population
This is a multi-center, retrospective cohort study. Kore-
an patients who were diagnosed with UC between July 
1987 and November 2013 at one of 11 tertiary hospitals 
were identified. All patients were diagnosed and treat-
ed by inflammatory bowel disease (IBD) specialists who 
are members of the Korean Association for the Study for 
Intestinal Diseases. The diagnosis of UC was based on 
accepted clinical, endoscopic, and histological findings 
[16]. Patients with the following conditions were exclud-
ed: incomplete medical records or diagnosis of other 
type of colitis including Crohn disease (CD), Behcet’s 
disease, or infectious colitis. The study population was 
classified into two groups according to the age of onset. 
Patients who were diagnosed before the age of 20 years 
were defined as the young-onset (YO) group and those 
diagnosed at or after the age of 20 years were assigned to 
the AO group. This study was approved by the Institu-
tional Review Board of each participating hospital.
Data collection and clinical outcomes
The baseline patient characteristics and clinical infor-
mation were collected retrospectively from the medi-
cal records of each participating hospital. The baseline 
characteristics included age at diagnosis, gender, body 
mass index (BMI), family history of IBD, smoking status, 
and follow-up duration. The disease state at diagnosis, 
including the Mayo score and the extent of disease, was 
also evaluated. The Mayo score is a 13-scale index (0 to 
12) that represents disease activity including stool fre-
quency, rectal bleeding, endoscopic findings, and a phy-
sician’s overall assessment [17]. The disease activity at 
diagnosis was measured using the Mayo score. A Mayo 
score of 3 to 5 was considered mild disease, 6 to 10 was 
moderate disease and 11 to 12 was severe disease. The ex-
tent of disease was determined by endoscopic findings 
and was categorized into three groups using the Mon-
treal classification [18]. A lesion extending from the anal 
verge to the rectosigmoid junction was defined as ulcer-
ative proctitis, disease to the distal part of the splenic 
flexure was defined as left-sided colitis and disease that 
extended beyond the splenic flexure was defined as ex-
tensive colitis. Each patients’ treatment during disease 
course were assessed according to the history of UC-re-
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lated admission and operation and, prior use of oral ste-
roids, intravenous (IV) steroids, immunosuppressants, 
or infliximab. A history of oral steroid use was limited 
to independent cases of IV steroid use. Severe outcomes 
were defined by the use of IV steroids, infliximab, im-
munosuppressants or UC-related operation.
Statistical analysis
SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) was used 
for all statistical analyses. The chi-square test or Fisher 
exact test was used for the analysis of categorical vari-
ables, such as gender, smoking status, disease activity 
at diagnosis, extent of disease, UC-related admission, 
UC-related operation, and medication use. Continuous 
variables including age, BMI, duration of follow-up, 
and Mayo score were analyzed using Student t test. Ka-
plan-Meier survival analysis was performed to identi-
fy factors associated with outcomes, and the log-rank 
test was used to evaluate any significant differences ac-
cording to each factor. Multivariate analysis using Cox 
proportional hazard regression was used to determine 
independent predictive factors, and these results were 
estimated using hazard ratios (HRs) and 95% confi-
dence intervals (CIs). In multivariate analysis, baseline 
characteristics at diagnosis were analyzed without treat-
ment-related factors in order to evaluate factors affect-
ing outcomes. The factors associated with treatment 
were analyzed using all variables. Results were consid-
ered statistically significant when p values were < 0.05.
RESULTS
Clinical characteristics and outcomes of the study 
population
A total of 1,141 patients with UC were included in the 
present study. The baseline patient characteristics are 
described in Table 1. The mean age at diagnosis was 
41.8 ± 14.3 years and the mean duration of follow-up was 
7.1 ± 4.2 years. Overall, 645 patients (56.5%) were male. 
Most patients were diagnosed with mild disease activ-
ity (52.3%) and ulcerative proctitis (43.9%). Furthermore, 
41.4% of patients were hospitalized for UC treatment 
and 5.5% underwent operation. The 43.2% of patients 
used oral steroid independently for treatment of UC. 
Comparison by age of onset 
A total of 55 patients (4.8%) were diagnosed with YO 
disease and 1,086 patients (95.2%) had AO disease. The 
mean age at diagnosis was 17.8 ± 2.4 years in the YO 
group and 43.0 ± 13.6 years in the AO group. The mean 
BMI was significantly lower in the YO group than it was 
in the AO group (19.8 ± 2.8 kg/m2 vs. 22.4 ± 3.1 kg/m2, p = 
0.000). Patients in the YO group smoked less frequently 
than those in the AO group (5.6% vs. 25.3%, p = 0.007). 
At the time of diagnosis, the YO group presented with 
a higher mean Mayo score than did the AO group (7.7 
± 3.0 vs. 5.6 ± 2.7, p = 0.000). Severe disease activity and 
Table 1. Baseline patient characteristics 
Characteristic
Total patients 
with UC (n = 1,141)
Age at diagnosis, yr 41.8 ± 14.3
Sex
Male 645 (56.5)
Female 496 (43.5)
Body mass index, kg/m2 22.3 ± 3.1
Family history of IBD 13/918 (1.4)
Smoking 186/762 (24.4)
Follow-up duration, yr 7.1 ± 4.2
Mayo score at diagnosis 5.7 ± 2.8
Disease activity at diagnosis
Mild 398/761 (52.3)
Moderate 278/761 (36.5)
Severe 85/761 (11.2)
Montreal classification of
 extent of UC
E1 (ulcerative proctitis) 501 (43.9)
E2 (left-sided UC) 331 (29.0)
E3 (extensive UC) 309 (27.1)
UC-related admission 472 (41.4)
UC-related operation 63 (5.5)
Medication
Oral steroids 493 (43.2)
IV steroids 219 (19.2)
Immunosuppressants 318 (27.9)
Infliximab 89 (7.8)
Values are presented as mean ± SD or number (%). Patients 
with missing values were not included in analysis. Data are 
expressed as raw numbers with proportions.
UC, ulcerative colitis; IBD, inflammatory bowel disease; IV, 
intravenous.
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extensive UC at diagnosis were more frequent in the YO 
group than they were in the AO group (28.6% vs. 10.3%, p 
= 0.000; 52.7% vs. 25.8%, p = 0.000, respectively) (Table 2).
During follow-up, there were no significant differenc-
es in UC-related admission or operation, or use of oral 
steroids between the two groups. However, IV steroids, 
immunosuppressants and infliximab were used more 
frequently in the YO group than they were in the AO 
group (41.8% vs. 18.0%, p = 0.000; 47.3% vs. 26.9%, p = 
0.002; 20.0% vs. 7.2%, p = 0.001, respectively) (Table 2).
Risk factors associated with severe outcomes
Patients were more likely to require IV steroids if they 
were diagnosed before the age of 20 years (HR, 2.01; 95% 
CI, 1.27 to 3.85; p = 0.005). Use of infliximab (HR, 3.37; 95% 
CI, 1.61 to 7.04; p = 0.001) and immunosuppressant (HR, 
2.13; 95% CI, 1.22 to 3.70; p = 0.008) were also more in-
creased in the YO group. However, there was no rela-
tionship between UC-related operation and the age at 
diagnosis (Table 3). The results of univariate and mul-
tivariate analyses of the risk factors associated with IV 
steroids, infliximab and immunosuppressants use and 
UC-related operation are described in Supplementary 
Tables 1-5. 
Table 4 and Fig. 1 describe the risk factors for severe 
outcomes. For the baseline characteristics at diagno-
sis, multivariate analysis identified that YO disease 
was significantly associated with increased risk of se-
Table 2. Baseline characteristics and outcomes by age of onset in ulcerative colitis patients
Characteristic Young-onset (n = 55) Adult-onset (n = 1,086) p value
Age at diagnosis, yr 17.8 ± 2.4 43.0 ± 13.6 0.000
Sex 0.560
Male 29 (52.7) 616 (56.7)
Female 26 (47.3) 470 (43.3)
Body mass index, kg/m2 19.8 ± 2.8 22.4 ± 3.1 0.000
Body mass index ≥ 23 kg/m2 7 (12.7) 446 (41.1)
Family history of IBD 1/45 (2.2) 12/886 (1.4) 0.628
Smoking 2/36 (5.6) 184/726 (25.3) 0.007
Follow-up duration, yr 7.0 ± 3.9 7.2 ± 4.2 0.819
Mayo score at diagnosis 7.7 ± 3.0 5.6 ± 2.7 0.000
Disease activity at diagnosis 0.000
Mild 8/35 (22.9) 390/726 (53.7)
Moderate 17/35 (48.5) 261/726 (36.0)
Severe 10/35 (28.6) 75/726 (10.3)
Montreal classification of extent of UC 0.000
E1 (ulcerative proctitis) 15 (27.3) 486 (44.8)
E2 (left-sided UC) 11 (20.0) 320 (29.5)
E3 (extensive UC) 29 (52.7) 280 (25.8)
UC-related admission 29 (52.7) 443 (40.8) 0.080
UC-related operation 4 (7.3) 59 (5.4) 0.560
Medication
Oral steroids 19 (34.5) 474 (43.6) 0.210
IV steroids 23 (41.8) 196 (18.0) 0.000
Immunosuppressants 26 (47.3) 292 (26.9) 0.002
Infliximab 11 (20.0) 78 (7.2) 0.001
Values are presented as mean ± SD or number (%). Patients with missing values were not included. Data are expressed as raw 
numbers with proportions.
IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous.
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vere outcomes (HR, 2.18; 95% CI, 1.27 to 3.71; p = 0.040). 
In addition, BMI < 23 kg/m2 (HR, 1.46; 95% CI, 1.07 to 
2.00; p = 0.018), moderate (HR, 2.48; 95% CI, 1.67 to 3.67; 
p = 0.000), and severe (HR, 2.29; 95% CI, 1.36 to 3.38; p 
= 0.002) disease activity at diagnosis, and extensive UC 
(HR, 2.90; 95% CI, 1.79 to 4.69; p = 0.000) were also relat-
ed to increased risk of severe outcomes. During treat-
ment, a history of UC-related admission (HR, 63.89; 
95% CI, 20.41 to 200.02; p = 0.000) was related to severe 
outcomes. In contrast, previous use of oral steroids (HR, 
0.51; 95% CI, 0.39 to 0.67; p = 0.000) decreased the risk of 
severe outcomes.
DISCUSSION
It is important to understand the clinical features and 
outcomes of UC with regard to the age of onset, because 
it may influence the proper treatment strategy to be 
used in clinical practice. The present study was the first 
large, multi-center and long-term study that analyzes 
the effects of age at disease onset. Our results suggest 
that age of onset is an important factor with regard to 
the clinical course of UC and, in particular, that clinical 
features and outcomes were more severe in UC patients 
with YO disease.
In the present study, we found that patients with YO 
disease had advanced clinical features at the time of di-
agnosis. Upon diagnosis, approximately 30% of YO pa-
tients had severe disease activity and more than 50% had 
extensive UC. In contrast, 50% of the patients in the AO 
group were initially diagnosed with mild disease activ-
ity and proctitis. The risk of IV steroid, infliximab and 
immunosuppressants use was also higher in the YO pa-
tients than it was in the AO patients. A previous study 
reported that patients younger than 17 years of age at di-
agnosis had more extensive disease and aggressive clin-
ical course, including steroid use than do those diag-
nosed after the age of 17 [9]. Previous population-based 
cohort studies have demonstrated that the number of 
relapses decreased with increasing age of onset [19]. In 
addition, a younger age at diagnosis has been found to 
be an independent predictor of earlier relapse, with an 
HR increase of 0.4 per decade [20]. Patients with late on-
set disease also have better responses to therapy and are 
more likely to experience steroid-free clinical remission 
1 year after diagnosis than are patients with YO disease 
[21]. Overall, the results of the present study are consis-
tent with those in the previous studies. 
 However, other reports have claimed that an older age 
of onset is related to poor outcomes in UC. A previous 
cross-sectional study found that patients 65 years and 
older were hospitalized more frequently and had higher 
in-hospital mortality and medical costs than did those 
diagnosed at a younger age [22]. However, this study 
was conducted using information from the Nationwide 
Table 3. Associations between age of ulcerative colitis onset and severe outcomes
Variable
Univariate analysis Multivariate analysis
7-Year cumulative rate, % p value HR (95% CI) p value
IV steroids, yr 0.000
≥ 20 15.0 Reference
< 20 36.1 2.01 (1.27–3.85) 0.005
Infliximab, yr 0.000
≥ 20 5.8 Reference
< 20 14.5 3.37 (1.61–7.04) 0.001
Immunosuppressants, yr 0.001
≥ 20 36.3 Reference
< 20 19.0 2.13 (1.22–3.70) 0.008
UC-related operation, yr 0.430
≥ 20 5.7 Reference
< 20 5.1 1.45 (0.41–5.17) 0.567
HR, hazard ratio; CI, confidence interval; IV, intravenous; UC, ulcerative colitis.
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Inpatient Samples; therefore, it is possible that their 
findings resulted from analysis of elderly patients with 
many comorbidities, and a secondary diagnosis of IBD. 
Similar results were seen in another population-based 
cohort study demonstrating that patients over the age 
of 50 at the time of diagnosis had increased mortality 
within the first two years of diagnosis than did those 
diagnosed at a younger age [23]. There were also more 
comorbidities reported in elderly patients, which were 
primarily attributed to their postoperative complica-
tions. Similarly, more severe outcomes and higher mor-
tality in elderly UC patients observed in previous studies 
may not reflect UC itself.
It is controversial how the age of UC onset influences 
Table 4. Risk factors of severe outcomes of ulcerative colitis patients
Characteristic
Univariate analysis Multivariate analysis
7-Year cumulative rate, % p value HR (95% CI) p value
Baseline at diagnosis
Age, yr 0.001
≥ 20 19.1 Reference
< 20 38.2 2.18 (1.27–3.71) 0.040
Sex 0.536
Female 19.3 Reference
Male 20.5 1.16 (0.84–1.60) 0.354
Body mass index, kg/m2 0.005
≥ 23 19.3 Reference
< 23 26.5 1.46 (1.07–2.00) 0.018
Family history of IBD 0.724
No 24.8 Reference
Yes 25.0 2.28 (0.71–7.34) 0.165
Smoking status 0.053
No 33.0 Reference
Yes 23.7 0.95 (0.65–1.41) 0.810
Disease activity at diagnosis 0.000
Mild 14.2 Reference
Moderate 46.9 2.48 (1.67–3.67) 0.000
Severe 49.8 2.29 (1.36–3.38) 0.002
Montreal classification of extent of UC 0.000
E1 (ulcerative proctitis) 6.7 Reference
E2 (left-sided UC) 22.3 1.38 (0.85–2.24) 0.197
E3 (extensive UC) 39.8 2.90 (1.79–4.69) 0.000
Treatment
UC-related admission 0.000
No 2.4 Reference
Yes 47.6 63.89 (20.41–200.02) 0.000
Medication
Oral steroids 0.607
No 31.1 Reference
Yes 30.7 0.51 (0.39–0.67) 0.000
HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UC, ulcerative colitis. 
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the need for UC-related operation. Studies from West-
ern countries have reported cumulative colectomy rates 
of 20% at 5 years and 25% at 10 years [24]. The rate of 
UC-related operation are lower in Asian patients than 
they are in Western patients, with a rate of 5.9% at 5 years 
and 10% of 10 years [25]. One Western study showed that 
the age of onset was younger in patients who had un-
dergone previous operation [26]. The actuarial risk of 
colectomy in that study was 7.5% at 5 years and 10.4% at 
10 years, higher than those of our study. Previous stud-
ies have suggested that the risk of operation does not 
differ by age of onset, with a previous study showing a 
higher proportion of steroid use in younger patients 
[27], although the other results were similar to ours. In 
our study, the UC-related operation rate was not signifi-
cantly different between the two groups. This finding 
may reflect the fact that a top-down strategy including 
biologic agents was more frequently used in YO pa-
tients than in AO patients because of their more severe 
disease state upon diagnosis. Operation becomes nec-
essary in UC when patients are medically refractory, or 
develop complications or colitic cancer. In the present 
study, extensive colitis at diagnosis was associated with 
an increased the risk of UC-related operation. Extensive 
inflammation may result in the development of compli-
cations and colitic cancer. 
The reasons behind the severe clinical features at di-
agnosis and the severe outcomes in UC with YO are not 
clear. It is possible that YO patients are simply detected 
earlier because they present with more severe symptoms 
than do older patients. In patients with mild features 
and a relatively narrow extent, disease may not be rec-
ognized early and therefore, in these patients it is di-
agnosed later, when symptoms arise. A previous study 
suggested that the pathophysiologic mechanisms of YO 
and AO disease differ [28]. It has also been reported that 
YO was a poor prognostic factor for several autoimmune 
diseases, including systemic lupus erythematosus and 
type 1 diabetes mellitus [29], and that genetic factors are 
more highly associated with YO disease than they are 
with AO disease [30]. Mild disease UC with proctitis in 
AO patients may result from a weak immunologic reac-
tion. Similar results have been observed in other immu-
nologic diseases [31]. 
A previous report also demonstrated that treatment 
responses were better in UC patients with a BMI < 25 
kg/m2 and in CD patients with a BMI > 25 kg/m2 than 
they are in larger patients [32]. However, the relationship 
between UC and BMI has not been clearly established. 
Alterations in fat and muscle may affect bone health, 
muscle performance, quality of life, and overall morbid-
ity. However, BMI does not accurately reflect body com-
position [33]. Interestingly, BMI < 23 kg/m2 increased the 
risk of severe outcomes in the present study. The BMI 
in the YO group was lower than in the AO group in this 
study, which is consistent with the pattern observed in 
the general population by age. BMI reflects the nutri-
tional status, which might be worse in patients with se-
vere disease. Smoking, which has been shown to have 
a well-established protective effect against UC [19], was 
more common in the AO group than in the YO group. 
However, it did not affect disease outcomes in the pres-
ent study. This finding may be related to the fact that 
most YO patients were minors, in whom smoking is 
prohibited. The association between smoking and UC 
does not appear to be very clear, as several other stud-
ies have argued that smoking does not have a protective 
effect against UC [34,35]. We also considered the finding 
that BMI and smoking increased with age. Further eval-
uation is needed to establish conclusive findings.
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Figure 1. The cumulative risk of severe outcomes was higher 
in young-onset patients than it was in adult-onset patients (p 
= 0.040). UC, ulcerative colitis.
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 This study has several limitations. There were only 55 
YO patients (4.8%) because data were collected from the 
Department of Internal Medicine’s medical records. In 
addition, the mean age of YO patients was also relatively 
high, and pediatric UC patients were not included. De-
spite the small number of patients; however, there were 
significant differences in the severity of clinical features 
and outcomes between the two groups in the present 
study. Relapse rate is an important factor that affects dis-
ease course and severe outcomes in UC. Unfortunately, 
the relapse rate could not be determined in the pres-
ent study. In addition, the results of outcomes analysis 
using patient history including UC-related admission 
and steroid use during follow-up after diagnosis of UC 
were limited because of inconsistent reference points. 
Further study is needed to confirm the associations and 
trends observed here. 
UC is a relapsing and remitting disease, currently with 
no cure. The purpose of treatment UC is to maintain re-
mission and prevent complications. Long-standing mu-
cosal inflammation can lead to complications and colitic 
cancer. Patients with YO UC suffer from the disease for 
a longer period of time than do AO patients. It is pos-
sible that severe outcomes including operation may be 
higher in YO patients compared to in AO patients with a 
prolonged follow-up. Intensive care and uninterrupted 
follow-up are especially important for YO patients. 
In conclusion, the present study revealed that age of 
disease onset has a major influence on UC. Patients with 
YO UC present with more advanced clinical features at 
diagnosis and experience more severe outcomes than 
do those with AO disease. Therefore, these results sug-
gest that careful management and an intense treatment 
strategy are necessary for YO patients.
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Supplementary Table 1. Baseline characteristics and outcomes by age of onset in ulcerative colitis patients
Characteristic
Age, yr
p value
1–19 (n = 55) 20–39 (n = 492) 40–59 (n = 453) ≥ 60 (n = 141)
Age of diagnosis, yr 17.8 ± 2.4 30.9 ± 5.4a 48.7 ± 5.3a,b 67.0 ± 5.3a,b,c 0.000
Sex 0.938
Male 29 (52.7) 277 (56.3) 259 (57.2) 80 (56.7)
Female 26 (47.3) 215 (43.7) 194 (42.8) 61 (43.3)
Body mass index, kg/m2 19.8 ± 2.8 21.8 ± 3.0a 22.9 ± 3.1a,b 22.5 ± 3.3a,b 0.243
Family history of IBD 1/45 (2.2) 7/387 (1.8) 3/377 (0.8) 2/122 (1.6) 0.628
Smoking 2/36 (5.6) 68/317 (21.5)a 84/307 (27.4)a 32/102 (31.4)a,b 0.006
Follow-up duration, yr 7.0 ± 3.9 7.4 ± 4.2 7.1 ± 4.3 6.5 ± 3.9 0.624
Mayo score at diagnosis 7.7 ± 3.0 5.8 ± 2.7a 5.4 ± 2.7a 5.5 ± 2.6a 0.389
Disease activity at diagnosis 0.000
Mild (3–5) 8/35 (22.9) 157/327 (48.0)a 183/305 (60.0)a,b 50/94 (53.2)a
Moderate (6–10) 17/35 (48.6) 132/327 (40.4) 91/305 (29.8)b 38/94 (40.4)
Severe (11–12) 10/35 (28.6) 38/327 (11.6)a 31/305 (10.2)a 6/94 (6.4)a
Montreal classification of
 extent of UC
0.000
E1 (ulcerative proctitis) 15 (27.3) 209 (42.5)a 210 (46.4)a 67 (47.5)a
E2 (left-sided UC) 11 (20.0) 128 (26.0) 144 (31.8) 48 (34.0)
E3 (extensive UC) 29 (52.7) 155 (31.5)a 99 (21.9)a,b 26 (18.5)a,b
UC-related admission 29 (52.7) 192 (39.0) 186 (41.1) 65 (46.1) 0.147
UC-related operation 4 (7.3) 22 (4.5) 27 (6.0) 10 (7.1) 0.533
Medication
Oral steroids 19 (34.5) 212 (43.1) 206 (45.5) 56 (39.7) 0.343
IV steroids 23 (41.8) 95 (19.3)a 70 (15.5)a 31 (22.0)a 0.000
Immunosuppressants 26 (47.3) 146 (29.7)a 111 (24.5)a 35 (24.8)a 0.003
Infliximab 11 (20.0) 40 (8.1)a 31 (6.8)a 7 (5.0)a 0.003
Severe outcomes 24 (43.6) 122 (24.8)a 97 (21.4)a 37 (26.2)a 0.004
Values are presented as mean ± SD or number (%). 
IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous.
ap < 0.05 compared with the 1–19 group.
bp < 0.05 compared with the 20–39 group.
cp < 0.05 compared with the 40–59 group.
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Supplementary Table 2. Risk factors of intravenous steroid use in ulcerative colitis patients
Characteristic
Univariate analysis Multivariate analysis
7-Year cumulative rate, % p value HR (95% CI) p value
Baseline at diagnosis
Age, yr 0.000
≥ 20 15.0 Reference
< 20 36.1 2.01 (1.27–3.85) 0.005
Sex 0.834
Female 16.5 Reference
Male 15.6 1.01 (0.71–1.42) 0.976
Body mass index, kg/m2 0.021
≥ 23 15.5 Reference
< 23 21.4 1.45 (1.03–2.04) 0.035
Family history of IBD 0.600
No 19.9 Reference
Yes 23.1 2.16 (0.67–7.00) 0.199
Smoking status 0.032
No 27.2 Reference
Yes 17.8 0.96 (0.62–1.48) 0.848
Disease activity at diagnosis 0.000
Mild 11.1 Reference
Moderate 39.7 2.48 (1.61–3.82) 0.000
Severe 35.3 1.78 (1.01–3.14) 0.048
Montreal classification of extent of UC 0.000
E1 (ulcerative proctitis) 4.9 Reference
E2 (left-sided UC) 16.8 1.44 (0.83–2.50) 0.200
E3 (extensive UC) 33.7 3.53 (2.06–6.04) 0.000
Treatment
UC-related admission 0.000
No 0.8 Reference
Yes 38.9 28.61 (8.95–91.50) 0.000
UC-related operation 0.000
No 14.5 Reference
Yes 41.3 1.62 (0.95–2.75) 0.075
Medication
Oral steroids 0.000
No 20.0 Reference
Yes 11.1 0.26 (0.18–0.37) 0.000
Immunosuppressants 0.000
No 7.9 Reference
Yes 48.7 2.40 (1.70–3.39) 0.000
Infliximab 0.000
No 13.1 Reference
Yes 60.5 1.22 (0.81–1.84) 0.349
HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UC, ulcerative colitis.
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Supplementary Table 3. Risk factors of infliximab use in ulcerative colitis patients
Characteristic 
Univariate analysis Multivariate analysis
7-Year cumulative rate, % p value HR (95% CI) p value
Baseline at diagnosis
Age, yr 0.000
≥ 20 5.8 Reference
< 20 14.5 3.37 (1.61–7.04) 0.001
Sex 0.070
Female 5.0 Reference
Male 7.1 1.54 (0.86–2.74) 0.147
Body mass index, kg/m2 0.122
≥ 23 6.6 Reference
< 23 7.4 1.40 (0.78–2.53) 0.258
Family history of IBD 0.228
No 7.6 Reference
Yes 13.0 1.82 (0.42–7.96) 0.428
Smoking status 0.550
No 10.3 Reference
Yes 7.4 1.11 (0.54–2.19) 0.775
Disease activity at diagnosis 0.000
Mild 4.0 Reference
Moderate 17.5 3.00 (1.58–5.73) 0.001
Severe 13.7 2.52 (1.08–5.90) 0.034
Montreal classification of extent of UC 0.000
E1 (ulcerative proctitis) 2.0 Reference
E2 (left-sided UC) 9.8 1.43 (0.58–3.51) 0.437
E3 (extensive UC) 8.9 1.39 (0.54–3.56) 0.495
Treatment
UC-related admission 0.000
No 2.0 Reference
Yes 12.3 1.17 (0.48–2.89) 0.729
UC-related operation 0.124
No 6.5 Reference
Yes 1.7 0.14 (0.02–1.02) 0.069
Medication
Oral steroids 0.067
No 4.6 Reference
Yes 8.0 1.49 (0.80–2.79) 0.210
IV steroids 0.000
No 2.8 Reference
Yes 22.0 2.01 (1.09–3.69) 0.024
Immunosuppressants 0.000
No 0.6 Reference
Yes 17.3 12.29 (4.70–32.11) 0.000
HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous.
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Supplementary Table 4. Risk factors of immunosuppressant use in ulcerative colitis patients
Characteristic
Univariate analysis Multivariate analysis
7-Year cumulative rate, % p value HR (95% CI) p value
Baseline at diagnosis
Age, yr 0.001
≥ 20 36.3 Reference
< 20 19.0 2.13 (1.22–3.70) 0.008
Sex 0.032
Female 16.7 Reference
Male 22.1 0.78 (0.56–1.09) 0.150
Body mass index, kg/m2 0.024
≥ 23 19.5 Reference
< 23 23.6 1.27 (0.92–1.75) 0.140
Family history of IBD 0.751
No 24.0 Reference
Yes 9.3 0.50 (0.12–2.05) 0.333
Smoking status 0.434
No 28.3 Reference
Yes 26.1 1.15 (0.79–1.68) 0.478
Disease activity at diagnosis 0.000
Mild 15.3 Reference
Moderate 45.2 1,97 (1.34–2.90) 0.001
Severe 42.3 2.21 (1.30–3.76) 0.003
Montreal classification of extent of UC 0.000
E1 (ulcerative proctitis) 7.1 Reference
E2 (left-sided UC) 26.4 2.80 (1.66–4.72) 0.000
E3 (extensive UC) 34.1 3.23 (1.89–5.54) 0.000
Treatment
UC-related admission 0.000
No 8.5 Reference
Yes 36.3 0.98 (0.62–1.53) 0.915
UC-related operation 0.011
No 18.9 Reference
Yes 34.2 1.16 (0.67–2.02) 0.591
Medication
Oral steroids 0.000
No 1.1 Reference
Yes 34.7 26.72 (6.71–114.58) 0.000
IV steroids 0.000
No 12.4 Reference
Yes 56.6 1.49 (1.03–2.16) 0.036
Infliximab 0.000
No 16.1 Reference
Yes 79.9 3.02 (2.11–4.30) 0.000
HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous. 
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Supplementary Table 5. Risk factors of ulcerative colitis-related operation in ulcerative colitis patients
Characteristic
Univariate analysis Multivariate analysis
7-Year cumulative rate, % p value HR (95% CI) p value
Baseline at diagnosis
Age, yr 0.430
≥ 20 5.7 Reference
< 20 5.1 1.45 (0.41–5.17) 0.567
Sex 0.389
Female 4.8 Reference
Male 3.0 0.59 (0.26–1.31) 0.192
Body mass index, kg/m2 0.642
≥ 23 4.1 Reference
< 23 4.7 0.97 (0.46–2.07) 0.937
Family history of IBD 0.453
No 4.5 Reference
Yes 0.0 - -
Smoking status 0.537
No 5.9 Reference
Yes 3.6 1.17 (0.42–3.27) 0.766
Disease activity at diagnosis 0.001
Mild 3.5 Reference
Moderate 4.6 1.14 (0.42–3.06) 0.796
Severe 13.1 2.24 (0.72–6.95) 0.163
Montreal classification of extent of UC 0.000
E1 (ulcerative proctitis) 2.0 Reference
E2 (left-sided UC) 2.4 0.70 (0.24–2.02) 0.507
E3 (extensive UC) 8.2 2.33 (1.01–5.40) 0.049
Treatment
UC-related admission 0.000
No 0.7 Reference
Yes 8.4 6.94 (1.50–32.21) 0.013
Medication
Oral steroids
No 3.0 0.029 Reference
Yes 4.8 3.18 (1.46–6.80) 0.004
IV steroids 0.000
No 1.8 Reference
Yes 12.8 2.62 (1.14–6.05) 0.024
Immunosuppressants 0.000
No 2.2 Reference
Yes 6.6 0.83 (0.37–1.86) 0.645
Infliximab 0.246
No 4.0 Reference
Yes 1.2 0.12 (0.02–0.89) 0.038
HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous. 
